Complete profile


Third-Party Information Liability Disclaimer

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.




Last Updated: 2014-03-14

Tekmira Pharmaceuticals Corporation

Company information

Logo  
 
Legal Name:   Tekmira Pharmaceuticals Corporation
Operating Name:   Tekmira Pharmaceuticals Corporation
 
Mailing Address
100-8900 Glenlyon Parkway
BURNABY, British Columbia
V5J 5J8
Location Address
100-8900 Glenlyon Parkway
BURNABY, British Columbia
V5J 5J8
 
Telephone: (604) 419-3200
Fax: (604) 419-3201
Email: info@tekmirapharm.com
Website URL: http://www.tekmirapharm.com 
 
Top

Contact information

 
Ian Mortimer
  Title:   Vice President
  Area of Responsibility:   Management Executive
  Telephone:   (604) 419-3200
  Fax:   (604) 419-3201
  Email:   imortimer@tekmirapharm.com
 

Top

Company description

 
Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's three lead RNAi product candidates target cholesterol management, cancer and Ebola infection. In addition to its pipeline of products, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.  
Country of Ownership: Canada  
Year Established: 2008
Exporting: Yes  
Primary Industry (NAICS): 325410 - Pharmaceutical and Medicine Manufacturing
Alternate Industries (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Manufacturer / Processor / Producer  
Number of Employees: 85 

Top

Product / Service / Licensing

 
Service Name: Development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi)
 
 

Top

Technology profile

As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.

Tekmira is uniquely equipped to become a force in this field. Guided by a cohesive vision, the Company possesses leading technology capabilities and a solid intellectual property portfolio in the area of using lipid nanoparticle (LNP) technology to deliver siRNA (small interfering RNA) as well as other nucleic acids in the treatment of disease.

With two RNAi drug candidates in clinical development and another in preclinical development, Tekmira is well positioned to aggressively advance its product strategy. In addition, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.

Finally, broad manufacturing capabilities and a strong capital position permit the Company to move forward decisively and build a solid base for both near and longer term growth.
Top

Market profile

Industry sector market interests:

  • Medical/Biotechnology/Chemical

Top



Note: This document is presented in the language provided by the author/source. Most of the information contained in Canadian Company Capabilities (CCC) has been provided by sources external to Industry Canada. The accuracy, currency and reliability of the information contained in CCC are the sole responsibility of the registered companies and related organizations. Industry Canada assumes no responsibility in this respect. The registered businesses shall ensure the continued monitoring of the information contained in CCC and ask that it be modified when necessary.